KRAS and lung carcinoma: Our data adds to the existing literature describing both the emergence of SMARCA4 loss at acquired resistance on targeted therapy38 but also an important co-mutation at baseline driving primary resistance, including the inhibition of KRAS G12C39,40 and EGFR mutant lung cancer with Osimertinib41.